Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.

Blood - 15 Mar 2004

Harada Hironori, Harada Yuka, Niimi Hiromasa, Kyo Taiichi, Kimura Akiro, Inaba Toshiya

Abstract excerpt

A high incidence of somatically acquired point mutations in the AML1/RUNX1 gene has been reported in poorly differentiated acute myeloid leukemia (AML, M0) and in radiation-associated and therapy-related myelodysplastic syndrome (MDS) or AML. The vast majority of AML1 mutations identified in these diseases were localized in the amino (N)-terminal region, especially in the DNA-binding Runt homology domain. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factor Alpha 2 Subunit
Share to COS Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dimerization

Share to HeLa Cells

Share to Incidence

Share to Leukemia, Myeloid

Share to Myelodysplastic Syndromes

Share to Transcription Factor AP-2

Source

Identifiers

PMID: 14615365
DOI: 10.1182/blood-2003-09-3074

Genes

RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.PMID 14615365Read ↗

Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.Semantic proximity Read ↗

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemiaSemantic proximity Read ↗

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutationsSemantic proximity Read ↗

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.Semantic proximity Read ↗

Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.Semantic proximity Read ↗

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation.Semantic proximity Read ↗

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high‐risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasiaSemantic proximity Read ↗

New mechanisms of AML1 gene alteration in hematological malignancies.Semantic proximity Read ↗

Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesisSemantic proximity Read ↗

AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.Semantic proximity Read ↗

AML1 mutations induced MDS and MDS/AML in a mouse BMT model.Semantic proximity Read ↗

Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.